Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.62B P/E - EPS this Y 23.90% Ern Qtrly Grth -
Income -183.77M Forward P/E -26.19 EPS next Y 39.10% 50D Avg Chg -
Sales 379.11M PEG - EPS past 5Y - 200D Avg Chg 25.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -
Recommedations 2.70 Quick Ratio 1.30 Shares Outstanding 97.26M 52W Low Chg 252.00%
Insider Own 48.61% ROA -18.22% Shares Float 50.86M Beta 2.15
Inst Own 56.21% ROE - Shares Shorted/Prior 8.39M/6.74M Price 26.98
Gross Margin 44.70% Profit Margin -48.47% Avg. Volume 1,091,060 Target Price 27.00
Oper. Margin -38.75% Earnings Date Jul 25 Volume 2,256,078 Change -0.04%
About Myovant Sciences Ltd.

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

MYOV Chatroom

User Image Rednovember24 Posted - 1 day ago

@MRTunity @Profitfire I’m also thinking a drop will happen to shake out more weaklings before the news. Sometime I’ll tell y’all about $MYOV. I see a similar replay of history here.

User Image Bigprofits23 Posted - 1 week ago

$MYOV https://www.fiercepharma.com/pharma/sumitomo-pharma-lays-another-400-us-staffers-face-sliding-revenues

User Image Bigprofits23 Posted - 1 week ago

$MYOV Awww to bad for Sumi after screwing the MYOV stock holders. Corruption has Karma! https://www.fiercepharma.com/pharma/sumitomo-pharma-lays-another-400-us-staffers-face-sliding-revenues

User Image sempiternal1 Posted - 2 weeks ago

$ARDX A double indication drug with large TAMs is pretty unusual. It’s even more unusual for it to still be owned by a small pharma. Maximum value for buyouts are generally at <12 months from last approval. I think this company has a better shot than most to get one in the next 6 months. Similar to $MYOV $ALBO. Also, X excitement will drive sp into earnings I imagine. Overall, I would love to see the bundling issue completely removed (75% chance per RJ report) but dialysis is a margin thin business. My guess is the new hire was brought in to negotiate around this issue and pitch on value as if bundling won’t happen. It’s better to let this ticker go at $16-$20 then let the full picture come into view. You start to run into patent life questions, length of full revenue, DCF gets smaller, etc. Sell big pharma on the dream now and let them fight out the details GL to all.

User Image Bigprofits23 Posted - 2 weeks ago

@newandimproveddonkeykong Sooo TRUE! I was in MYOV for 4 years! Yikes. Road from 8 to 31 back to 7’s, then BO at $27. I knew what I owned even though lowball BO because they had a majority stock holder. Was also in PRVB with the money from MYOV. In at 7 out at BO of $25. $ARDX seems like a much easier hold and buy than $MYOV or $PRVB. GL!

User Image NobVega Posted - 1 month ago

$ARQT I said $IMGN and $MYOV would be bought out. I'm saying the same here. I'm only holding 8k shares, but expect a $20 buyout from here.

User Image Lets_Go_Brndn Posted - 1 month ago

$BTTX Frank talks Tuesday. Listen to what a successful CEO has to say. And don’t forget his involvement in $MYOV. Frank doesn’t know anything but success. “Media” pop-up writes come and go like diarrhea in a diaper. Very similar

User Image west281356 Posted - 02/19/24

@airplaneb747 @R408 reminds me of the $MYOV Take under at $27….

User Image Quad_ Posted - 2 months ago

@stelzer $IMMU and $MYOV were, too.

User Image Bigprofits23 Posted - 01/24/24

@Bamabeast256 If there was evidence it would be illegal, right? I have been involved in 2 BO’s over the last 15 months. $MYOV & $PRVB ARDX seems to have the best management team out of the 3. That would be the only reason I would say NA to a BO unless it was relatively high. But as I SPECULATE the previous BO’s were $27 & $25 respectively. GL!

User Image RTuckr Posted - 01/19/24

@Governor_Richie @Elvira007 @Governor_Richie @Elvira007 there would be an announcement saying… MREO has agreed to be bought by XYZ @$9.00. The buyout takes time(2-6months) but in the short term, before the deal finalizes, it would trade at $8.xx - gets closer to 9 the more imminent the date is. Any shares you still own by the acquisition date will turn to cash. See $MYOV.

User Image fin_researcher Posted - 4 months ago

$MYOV Myovant Sciences was acquired by Sumitovant of Sumitomo Pharma for $27.00 per share in cash via a merger transaction. Based on J.P. Morgan's valuations for $MYOV, Sumitovant was willing to pay $29.50 per share in a competitive bidding scenario. Investors suspect that they were misled in voting for a merger at a price that was less than Myovant’s full and fair value. https://11thestate.com/cases/myovant-mna-lawsuit

User Image nosoul777 Posted - 11/30/23

$IMGN gosh, I love it when I'm right! Number 5 for me in the past year-ish. $MYOV, $PRVB, $SPPI, $ALBO and now $IMGN. I wish I had more money in here right now, but I'll take a win wherever I get it these days. 🙂

User Image fin_researcher Posted - 11/27/23

$MYOV Myovant Sciences was acquired by Sumitovant of Sumitomo Pharma for $27.00 per share in cash via a merger transaction. Based on J.P. Morgan's valuations for $MYOV, Sumitovant was willing to pay $29.50 per share in a competitive bidding scenario. Investors suspect that they were misled in voting for a merger at a price that was less than Myovant’s full and fair value. To claim compensation: https://11thestate.com/cases/myovant-mna-lawsuit

User Image Quad_ Posted - 5 months ago

$AUPH It’s always important to remember there will be wolves in sheep’s clothing on StockTwits. Happened in $MYOV with my beloved friend Fade. To this day, I’m pretty sure Fade was Myrtle’s bitch. Some knowledge, fancy charts, and then some FUD. Some of that is happening here, too. This will get bought. Just be careful who you listen to here. Chances are you’re talking to some mid level hedge fund guy that just got over a bender and has to protect his firms short position… or accumulate.

User Image mrmark47299 Posted - 10/31/23

$TTOO I did this for 2 year's with $MYOV GOT BOUGHT OUT, AND THEN I THREW IT ALL AWAY WITH $TTOO. (BUT I AINT SELLING)!

User Image mrmark47299 Posted - 10/31/23

@momneedsnewshoes I did this for 2 year's with $MYOV GOT BOUGHT OUT, AND THEN I THREW IT ALL AWAY WITH $TTOO. (BUT I AINT SELLING)!

User Image Auphiliate Posted - 10/26/23

@Goodfriend98 @Valleycapital @TonyK666 Learned my lesson here. Best to go with biotechs with better sales potential. $TGTX and most recently $MYOV for me! Lupkynis is a good product but smaller patient population and too easy for greedy management to stuff their pockets then hide behind a million excuses. Yes, there are many other similar biotechs. I will avoid them as well. 🧐

User Image fin_researcher Posted - 10/24/23

Investors who faced losses from the $MYOV stock dip may have a chance for recovery. https://11thestate.com/cases/myovant-mna-lawsuit

User Image jnc1631 Posted - 10/18/23

@Bobes almost thought you were talking about Dave Marek from $MYOV. I still have flashbacks to that brutal experience. Maybe Daves are bad luck

User Image stockilluminati Posted - 6 months ago

$MYOV https://clinicaltrials.gov/study/NCT05862272 - trial update posted here!

User Image Quad_ Posted - 6 months ago

$AUPH You know you're about to get bought out when the company stops doing PR's. Patent news and the news below is evidence of that. Crickets from management. This is exactly what happened with $MYOV. Sure hope Tony is OK and didn't get Carlosed.

User Image stockilluminati Posted - 6 months ago

$MYOV https://www.stockilluminati.com/myov/news.php - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

User Image fin_researcher Posted - 6 months ago

$MYOV

User Image shoddy Posted - 6 months ago

@Buckeye80 Same happened when I was looking to buy $MYOV it dropped and was the perfect time to buy yet wanted to hold this junk longer and missed that BO also $TRIL another quick turnaround from a decline to BO. Let’s hope this is the end here for AUP

User Image stockilluminati Posted - 6 months ago

$MYOV https://www.stockilluminati.com/myov/display.php?url=https://clinicaltrials.gov/study/NCT05879913 - trial update posted here!

User Image nosoul777 Posted - 6 months ago

$AUPH long time lurker, first time posting. I've been involved in 4 BOs in the past 12mo ($MYOV, $ALBO, $SPPI, and $PRVB) and this stock follows none of them. Sure, there's an occasional comparison that can be made, but this is in a league of its own as far as the crazy goes. I never really realized how much the CEO mattered. Now I know, and I will pay much closer attention to this in future investments.

User Image TrendyChart Posted - 6 months ago

Upcoming Earnings Report: $MYOV Myovant Sciences will be reporting on 10/25/2023 at 8:00AM What's your take on the earnings potential of this stock?

User Image cctranscripts Posted - 09/29/23

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV https://conferencecalltranscripts.com/summary/?id=528537&pr=true $MYOV

User Image stockilluminati Posted - 09/29/23

$MYOV https://www.stockilluminati.com/myov/news.php - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Analyst Ratings
Evercore ISI Group In-Line Oct 26, 22
SVB Leerink Market Perform Oct 25, 22
Baird Neutral Oct 24, 22
SVB Leerink Outperform Aug 9, 22
Goldman Sachs Neutral Jul 28, 22
Goldman Sachs Neutral May 11, 22
SVB Leerink Market Perform Apr 13, 22
SVB Leerink Market Perform Feb 16, 22
SVB Leerink Market Perform Jan 5, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sumitomo Chemical Co., Ltd. 10% Owner 10% Owner Mar 10 Buy 27.00 51,599,200 1,393,178,400 45,798,176 03/10/23
Lang Matthew General Counsel & Co.. General Counsel & Corp. Secy. Jan 18 Sell 26.89 1,272 34,204 354,303 01/20/23
Merendino Lauren Chief Commercial Off.. Chief Commercial Officer Jan 18 Sell 26.89 2,008 53,995 169,538 01/20/23
Marek David C Principal Executive.. Principal Executive Officer Jan 18 Sell 26.89 8,037 216,115 417,599 01/20/23
Arjona Ferreira Juan Camilo Chief Medical Office.. Chief Medical Officer Jan 04 Sell 26.90 2,251 60,552 247,793 01/05/23
Lang Matthew General Counsel & Co.. General Counsel & Corp. Secy. Jan 04 Sell 26.90 2,779 74,755 355,575 01/05/23
Mehra Uneek Principal Financial.. Principal Financial Officer Dec 16 Sell 26.75 2,241 59,947 202,696 12/20/22
Merendino Lauren Chief Commercial Off.. Chief Commercial Officer Oct 18 Sell 25.20 1,703 42,916 171,546 10/20/22
Marek David C Principal Executive.. Principal Executive Officer Oct 18 Sell 25.20 11,156 281,131 425,636 10/20/22
Lang Matthew General Counsel & Co.. General Counsel & Corp. Secy. Oct 18 Sell 25.20 1,933 48,712 358,354 10/20/22
Arjona Ferreira Juan Camilo Chief Medical Office.. Chief Medical Officer Oct 18 Sell 25.20 1,604 40,421 250,044 10/20/22
Mehra Uneek Principal Financial.. Principal Financial Officer Sep 16 Sell 18.86 9,243 174,323 204,937 09/20/22
Lang Matthew General Counsel & Co.. General Counsel & Corp. Secy. Aug 12 Sell 18.23 31,214 569,031 363,966 08/16/22
Lang Matthew General Counsel & Co.. General Counsel & Corp. Secy. Jul 18 Sell 12.87 1,935 24,903 270,400 07/20/22
Merendino Lauren Chief Commercial Off.. Chief Commercial Officer Jul 18 Sell 12.87 1,704 21,930 173,249 07/20/22
Marek David C Principal Executive.. Principal Executive Officer Jul 18 Sell 12.87 11,164 143,681 436,792 07/20/22
Arjona Ferreira Juan Camilo Chief Medical Office.. Chief Medical Officer Jul 06 Sell 13.40 2,755 36,917 255,992 07/08/22